Data updated: May 26, 2026
FASLODEX (fulvestrant)
Estrogen Receptor Antagonists
Trial Activity: Stable 121 active trials
Oncology
Approved 2002-04-25
Faslodex (fulvestrant) is an estrogen receptor antagonist used to treat hormone receptor (HR)-positive, HER2-negative advanced breast cancer in postmenopausal women, both as a first-line treatment and for disease progression following endocrine therapy. It is also indicated for HR-positive, HER2-negative advanced or metastatic breast cancer in combination with CDK4/6 inhibitors: with ribociclib as initial or subsequent therapy in postmenopausal women, or with palbociclib or abemaciclib in women whose disease has progressed after endocrine therapy.
How FASLODEX Works
Fulvestrant is a selective estrogen receptor degrader (SERD). It binds competitively to estrogen receptors (ER) with an affinity comparable to estradiol. By binding to the ER, fulvestrant inhibits receptor dimerization, prevents nuclear localization, and leads to the dose-dependent downregulation and degradation of the estrogen receptor protein. This mechanism effectively inhibits the growth of estrogen-sensitive breast cancer cell lines without exhibiting any agonist-type (estrogen-like) effects.
Development Insights
Novartis Pharmaceuticals conducting 21 trials (8%)
256 indications explored (Broad Platform)
→ breast cancer (85 trials)
→ metastatic breast cancer (51 trials)
→ advanced breast cancer (23 trials)
13
Indications
--
Phase 3 Trials
4
Priority Reviews
24
Years on Market
Details
- Status
- Prescription
- First Approved
- 2002-04-25
- Routes
- INTRAMUSCULAR
- Dosage Forms
- SOLUTION
FASLODEX Approval History
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
62 FDA actions from 2002 to 2021 · 12 indication expansions
Oct 2016 SUPPL
Mfg
Aug 2014 SUPPL
Mfg
Jun 2014 SUPPL
Mfg
Oct 2013 SUPPL
Mfg
What FASLODEX Treats
1 indicationsFASLODEX is approved for 1 conditions since its original approval in 2002. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Breast Cancer
Source: FDA Label
FASLODEX Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
6
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
8
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
10
Same indication, different mechanism — what else might this patient receive?
Unlock 18 more competitors across all three rings.
Upgrade to Pro Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in FASLODEX's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications FASLODEX treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to FASLODEX
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
📋
Clinical Trial Registry
267 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06110793 | 23-274 | Ph 1, Ph 2 | recruiting | A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer |
| NCT06979596 | 5684-015 2024-519563-18-00, U1111-1315-5430 | Ph 2 | recruiting | A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) |
| NCT05564377 | NCI-2022-06842 NCI-2022-06842, EAY191 | Ph 2 | recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial |
| NCT07287917 | AMXT1501-103 | Ph 1, Ph 2 | recruiting | Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors |
| NCT07288359 | CGVV858A12101 2025-521911-38 | Ph 1, Ph 2 | recruiting | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors |
| NCT07368998 optINAVO | WO46063 2025-522805-39-00 | Ph 2 | recruiting | To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer |
| NCT07226349 | BG-75098-101 2025-523165-19-00 | Ph 1 | recruiting | A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors |
| NCT05319873 | 21-001819 NCI-2021-11707 | Ph 1, Ph 2 | active not recruiting | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer |
| NCT06257264 | BG-68501-101 CTR20243059, 2024-517324-19-00 | Ph 1 | recruiting | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors |
| NCT07318805 | C6321001 2025-524387-38-00 | Ph 1 | recruiting | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors |
| NCT06982521 ReDiscover-2 | RLY-2608-102 | Ph 3 | recruiting | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer |
| NCT05601440 | I241 | Ph 2 | recruiting | Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer |
| NCT05646862 INAVO121 | WO43919 2022-502322-41-00 | Ph 3 | active not recruiting | A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy |
| NCT07062965 | C4551002 2025-520566-22-00 | Ph 3 | recruiting | A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. |
| NCT07570966 | CERW316A12101 2025-521913-16 | Ph 1, Ph 2 | not yet recruiting | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors |
| NCT06065748 | CO44657 2022-502980-39-00 | Ph 3 | recruiting | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) |
| NCT03179904 results posted | MC1633 W81XWH-16-1-0269, W81XWH-16-1-0268 | Ph 2 | active not recruiting | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer |
| NCT06998407 AVZO-023-1001 | AVZO-023-1001 | Ph 1, Ph 2 | recruiting | ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors |
| NCT04305496 CAPItello-291 results posted | D3615C00001 2023-505042-25-00, 2019-003629-78 | Ph 3 | active not recruiting | Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer |
| NCT05306340 | ML43171 2022-000199-20, 2023-506821-12-00 | Ph 3 | active not recruiting | A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) |
| NCT05608252 | 22-490 | Ph 1, Ph 2 | recruiting | VS-6766+Abema+Fulv in Met HR+/HER- BC |
| NCT07558733 | FTH-PIK-101 | Ph 1, Ph 2 | recruiting | Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer |
| NCT05870579 | CAAA603B12101 2022-502465-18-00 | Ph 1 | recruiting | [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer |
| NCT03633331 results posted | A171601 NCI-2017-01596 | Ph 2 | completed | Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer |
| NCT07174336 | 27726 J6M-MC-JSGD, 2025-522791-92-00 | Ph 3 | recruiting | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) |
| NCT03939897 results posted | NCI-2019-02752 NCI-2019-02752, 201911082 | Ph 1 | active not recruiting | Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer |
| NCT06726148 | CECI830A12101 2024-517281-42 | Ph 1, Ph 2 | recruiting | Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors |
| NCT06428396 | 6482-029 MK-6482-029, LITESPARK-029 | Ph 2 | recruiting | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) |
| NCT05768139 PIKALO-1 | 27691 2023-504807-94-00, 2023-000442-41 | Ph 1, Ph 2 | recruiting | First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors |
| NCT05683418 | TOS-358-001 2023-505346-26-01 | Ph 1 | recruiting | A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer |
| NCT06997029 | CA243-0001 2025-524334-26-00, U1111-1330-3304 | Ph 1 | recruiting | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors |
| NCT05307705 PIKASSO-01 | 18394 2022-000175-40, J4C-OX-JZUA | Ph 1 | active not recruiting | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors |
| NCT04862663 CAPItello-292 | D361DC00001 2020-004637-20 | Ph 3 | recruiting | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) |
| NCT07405801 | CO46274 2025-523013-28-00 | Ph 2 | recruiting | A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer |
| NCT06179303 | RG1122019 NCI-2022-06409, FHIRB0020029 | Ph 2 | recruiting | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer |
| NCT04606446 KAT6 | C4551001 NCT04606446 | Ph 2 | recruiting | Study of PF-07248144 in Advanced or Metastatic Solid Tumors |
| NCT06120283 | BGB-43395-101 2023-506888-34-00, CTR20243370 | Ph 1 | recruiting | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors |
| NCT05238922 | INCB 123667-101 2021-005357-91 | Ph 1 | recruiting | Study of INCB123667 in Subjects With Advanced Solid Tumors |
| NCT06380751 EvoPAR-BR01 | D9722C00001 | Ph 3 | recruiting | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer |
| NCT07408089 KOMODO-1 | BBI-940-101 | Ph 1 | recruiting | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer |
| NCT06625775 | TBBO10203-101 2024-519445-29-00, BREAKER-101 | Ph 1 | recruiting | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors |
| NCT04650581 FINER results posted | MA40 2101, M041883 | Ph 3 | active not recruiting | Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor |
| NCT05467891 RaPhLRR | HCRN BRE20-468 | Ph 2 | recruiting | Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer |
| NCT04524000 | CBYL719C1201 | Ph 2 | active not recruiting | Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer |
| NCT06764186 CAPItana | D3612L00005 | Ph 3 | active not recruiting | A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain |
| NCT05038735 EPIK-B5 | CBYL719C2303 2023-509133-39-00 | Ph 3 | active not recruiting | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. |
| NCT05631795 ALPINIST | CBYL719CIN01 | Ph 4 | completed | Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment |
| NCT04544189 | CBYL719C2201 | Ph 2 | active not recruiting | Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer |
| NCT05161195 | CLEE011A2412B 2024-514891-41-00 | Ph 4 | active not recruiting | Roll-over Study to Allow Continued Access to Ribociclib |
| NCT05735080 INX-315-01 | INX-315-01 | Ph 1, Ph 2 | recruiting | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer |
Showing 50 of 267 trials
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
FASLODEX FDA Label Details
Indications & Usage
FDA Label (PDF)FASLODEX is indicated for the treatment of Breast Cancer.
Track FASLODEX with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment